Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia
Acute Myeloid Leukaemia (AML) is a rare but serious group of diseases that require critical decision-making for curative treatment. Over the past decade, scientific discovery has revealed dozens of prognostic gene mutations for AML while sequencing costs have plummeted. In this study, we compared th...
Автори: | Cressman, S, Karsan, A, Hogge, DE, McPherson, E, Bolbocean, C, Regier, DA, Peacock, SJ |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
Wiley
2016
|
Схожі ресурси
-
Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada
за авторством: Sonya Cressman, та інші
Опубліковано: (2020-07-01) -
Acute Myeloid Leukaemia with Plasmacytosis
за авторством: Yasmin Akhtar, Saqib Qayyum Ahmad, Shahid Jamal
Опубліковано: (2016-12-01) -
Exploring the acute myeloid leukaemias
за авторством: TB Thapa
Опубліковано: (2013-10-01) -
Secondary acute myeloid leukaemia in children treated for acute lymphoblastic leukaemia.
за авторством: Eden, O, та інші
Опубліковано: (1998) -
Acute myeloid leukaemia with aberrant expression of pancytokeratin: A diagnostic pitfall
за авторством: Yasin Dhonye, та інші
Опубліковано: (2023-02-01)